About Eleven Biotherapeutics (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-2.96
Forward P/E Ratio-6.33
Sales & Book Value
Price / Sales365.65
Price / CashN/A
Book Value$0.49 per share
Price / Book6.71
EPS (Most Recent Fiscal Year)($1.11)
Return on Equity-126.96%
Return on Assets-33.38%
Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions
What is Eleven Biotherapeutics' stock symbol?
Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."
How were Eleven Biotherapeutics' earnings last quarter?
Eleven Biotherapeutics (NASDAQ:EBIO) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.
What price target have analysts set for EBIO?
2 brokers have issued 12-month price targets for Eleven Biotherapeutics' shares. Their predictions range from $2.00 to $8.00. On average, they expect Eleven Biotherapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Eleven Biotherapeutics.
Are investors shorting Eleven Biotherapeutics?
Eleven Biotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 6,739,239 shares, an increase of 48.5% from the April 30th total of 4,536,882 shares. Based on an average daily trading volume, of 6,663,859 shares, the short-interest ratio is presently 1.0 days.
Who are some of Eleven Biotherapeutics' key competitors?
Some companies that are related to Eleven Biotherapeutics include Kura Oncology (KURA), Aduro BioTech (ADRO), Akebia Therapeutics (AKBA), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), ZIOPHARM Oncology (ZIOP), Lannett (LCI), Keryx Biopharmaceuticals (KERX), Beyondspring (BYSI), Five Prime Therapeutics (FPRX), Insys Therapeutics (INSY), Prothena (PRTA), AC Immune (ACIU), Cara Therapeutics (CARA) and Obseva (OBSV).
Who are Eleven Biotherapeutics' key executives?
Eleven Biotherapeutics' management team includes the folowing people:
- Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
- Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
- Dr. Gregory L. Verdine, Co-Founder (Age 59)
- Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
- Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board
Has Eleven Biotherapeutics been receiving favorable news coverage?
Media stories about EBIO stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a news impact score of 0.05 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 44.34 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Eleven Biotherapeutics' major shareholders?
Eleven Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
SABBY MANAGEMENT, LLC
SABBY MANAGEMENT, LLC
(7.40%), Highbridge Capital Management LLC (3.33%), Sabby Management LLC (2.57%) and Millennium Management LLC (0.51%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.
Which institutional investors are buying Eleven Biotherapeutics stock?
How do I buy shares of Eleven Biotherapeutics?
Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eleven Biotherapeutics' stock price today?
One share of EBIO stock can currently be purchased for approximately $3.29.
How big of a company is Eleven Biotherapeutics?
Eleven Biotherapeutics has a market capitalization of $159.20 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.
How can I contact Eleven Biotherapeutics?
Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]
MarketBeat Community Rating for Eleven Biotherapeutics (EBIO)MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.